Supplementary data from: Effect of mass azithromycin distribution on antibiotic resistance in the gut and nasopharynx: A cluster-randomized trial

The data contained in this repository was collected as part of a trial that studies the effects of repeated twice-yearly azithromycin mass drug distribution (MDA) in a pediatric population enrolled in a clinical trial in Niger. MDA has been shown to reduce all-cause childhood mortality, but the potential selection of antibiotic resistance (AMR) is a major public health concern. The repository contains supporting material describing the sequencing quality of samples, while the host-cleaned sequencing data itself can be found in the Sequencing Read Archive (SRA) under BioProject ID PRJNA1337442.
, , # Supplementary data from: Effect of mass azithromycin distribution on antibiotic resistance in the gut and nasopharynx: A cluster-randomized trial

## Description of the data and file structure

This repository contains supporting material that describes the sequencing depth of nasopharyngeal and rectal samples. The sequencing data (host-cleaned fastq files) can be found in the Sequencing Read Archive (SRA) under [BioProject ID PRJNA1337442](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1337442).

This data was collected as part of a trial that studies the effects of repeated twice-yearly azithromycin mass drug distribution (MDA) in Niger. MDA has shown to reduce all-cause childhood mortality, but the potential selection of antibiotic resistance (AMR) is a major public health concern.

## Data availability

Individual-level metadata linking samples to pooling, site, and treatment arm information contains human subjects data with direct and indirect identifiers and cannot be shared in th..., This dataset was collected as part of the AVENIR clinical trial, which received ethics approval and informed consent was obtained in accordance with the study protocol. Participants (or their guardians) provided consent for the collection and use of biological samples for research purposes, including the sharing of de-identified, aggregate-level data.

The data deposited here contain only sequencing quality metrics (read pair counts and filtering statistics) and do not include any direct or indirect identifiers of individual participants. De-identification was achieved through the following measures:

1. **Sample pooling:** Each sample represents a pool of multiple individuals' nasopharyngeal or rectal specimens. Sequencing reads were host-cleaned before analysis, making identification at the individual level impossible from the sequencing data alone.
2. **Randomized sample identifiers:** Sample IDs are randomized integer codes with no link to participant identities.
3. **Restricted con...,

本仓库所包含的数据，源自尼日尔一项针对儿科人群的临床试验，该试验旨在探究每半年一次的重复阿奇霉素大规模药物配送（mass drug distribution, MDA）的干预效果。已有研究证实，MDA可降低全因儿童死亡率，但抗生素耐药性（Antimicrobial Resistance, AMR）的潜在筛选风险是重大公共卫生关切。本仓库包含描述样本测序质量的辅助材料，而经宿主序列清除的测序数据本身，可在序列读取档案（Sequencing Read Archive, SRA）的生物项目编号PRJNA1337442下获取。
# 补充数据来源：《阿奇霉素大规模配送对肠道与鼻咽部抗生素耐药性的影响：一项整群随机试验》

## 数据与文件结构说明
本仓库包含用于描述鼻咽及直肠样本测序深度的辅助材料。经宿主序列清除的FASTQ格式测序数据，可在序列读取档案（SRA）的[生物项目编号PRJNA1337442](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1337442)下获取。
本数据集源自尼日尔一项试验，该试验旨在探究每半年一次的重复阿奇霉素大规模药物配送（MDA）的干预效果。MDA可降低全因儿童死亡率，但抗生素耐药性（AMR）的潜在筛选风险仍是重大公共卫生关切。

## 数据可用性说明
关联样本与混样信息、采集位点及治疗组信息的个体级元数据，包含带有直接及间接识别标识的人类受试者数据，无法公开共享……本数据集隶属于AVENIR临床试验，该试验已获得伦理审查批准，且所有受试者（或其监护人）均按照研究方案签署了知情同意书。受试者（或其监护人）同意收集并使用其生物样本用于科研，包括共享去标识化的汇总级数据。
本仓库存储的数据仅包含测序质量指标（读段对计数及过滤统计数据），不包含任何个体参与者的直接或间接识别标识。本次去标识化通过以下措施实现：
1. **样本混样：** 每份样本均为多名个体的鼻咽或直肠标本的混合样本。测序读段在分析前已完成宿主序列清除，仅通过测序数据无法实现个体层面的识别。
2. **随机化样本标识符：** 样本编号为随机整数代码，与参与者身份无任何关联。
3. **限制性……（原文截断）**